Protocol
12-002
Full Title
A Phase II Study of BKM120 for Patients with Recurrent Glioblastoma and Activated PI3K Pathway
Purpose
The PI3 kinase (PI3K) pathway is a molecular signaling pathway that is activated in some cancers and promotes cancer growth. BKM120 is an investigational drug designed to kill cancer cells by inhibiting the PI3K pathway. In this study, researchers are evaluating the safety and effectiveness of BMK120 in patients with glioblastoma that has returned or continued to grow despite prior treatment.
BMK120 is taken orally (by mouth).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have glioblastoma that has returned or continues to grow despite standard therapy and shows evidence of an activated PI3K pathway.
- At least 4 weeks must have passed since completion of prior therapies (6 weeks since antibody therapy and 12 weeks since radiation therapy) before a patient enters the study.
- Patients may not have had prior treatment with a PI3K inhibitor, mTOR inhibitor, AKT inhibitor, or drugs that target vascular endothelial growth factor (such as bevacizumab, cediranib, aflibercept, vandetanib, or sunitinib).
- Patients must be age 18 or older.
Disease(s)
Pediatric Brain Tumors: Brain Cancer
Locations
Related Diseases
